New insider activity at Insmed ( (INSM) ) has taken place on November 26, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Elizabeth M. Anderson has recently executed a significant transaction by selling 5,000 shares of Insmed stock, amounting to a total value of $1,022,900.
Recent Updates on INSM stock
In the last 24 hours, Insmed has seen significant developments following its Q3 earnings call. The company reported a successful launch of BRINSUPRI with $28 million in net sales and a strong performance from ARIKAYCE, which led to an increase in its 2025 full-year revenue guidance. Insmed’s regulatory progress with brensocatib in the EU and its robust pipeline, including potential Phase III programs for TPIP, are seen as key drivers for future growth. Analysts have raised price targets for Insmed, citing the successful launch of BRINSUPRI, the anticipated commercial opportunity from its FDA approval, and the company’s strong financial position with $1.7 billion in cash. However, challenges remain in the early market access dynamics for BRINSUPRI, with uncertainties around reimbursement criteria potentially impacting future performance.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s stock score is primarily impacted by its financial performance challenges, despite strong technical indicators and positive earnings call highlights. The company’s ongoing losses and cash flow issues weigh heavily, though recent product successes and bullish market trends provide some optimism.
To see Spark’s full report on INSM stock, click here.
More about Insmed
YTD Price Performance: 198.81%
Average Trading Volume: 2,376,073
Technical Sentiment Signal: Buy
Current Market Cap: $44.58B